Abstract
Fas is a transmembrane receptor that can induce apoptosis after cross-linking with either agonistic antibodies or with Fas ligand (FasL). Although originally described as an important regulator of peripheral immune homeostasis, accumulating evidence suggests that the Fas/FasL system plays an important role in tumour development. In addition to its proapoptotic functions, accumulating evidence demonstrates that Fas can activate numerous nonapoptotic signalling pathways, and that activation of these pathways can result in increased tumourigenicity and metastasis. This review summarises the current understanding of the Fas/FasL system in tumorigenesis and discusses attempts to utilise the Fas/FasL system in the treatment of cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 1031-1044 |
| Number of pages | 14 |
| Journal | Expert Opinion on Therapeutic Targets |
| Volume | 9 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Oct 2005 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Apoptosis
- Chemotherapy
- Drug resistance
- Fas ligand/CD95L
- Fas/CD95
- Inflammation
- Interferon (IFN)-γ
Fingerprint
Dive into the research topics of 'Targeting the Fas/Fas ligand pathway in cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver